Figure 4.

Among patients with severe NPDR or worse, intravitreal injections of anti-VEGF agents has tended to reduce retinopathy progression and an increase retinopathy regression (Elman et al. 2010). A similar association was also observed in the rates of panretinal photocoagulation and vitreous hemorrhage, which are clinical surrogates of retinopathy progression to proliferative disease (3%, P = 0.002 and 3%, P = 0.02, respectively, vs. 8%). (Figure derived from Elman et al. 2010; reprinted, with permission, from the author.)